ProShares UltraShort NASDAQ Biotechnology
19 hedge funds and large institutions have $19.6M invested in ProShares UltraShort NASDAQ Biotechnology in 2015 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
46% more funds holding
Funds holding: 13 → 19 (+6)
11% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $10.3M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $19.9M → $19.6M (-$269K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$2.07M |
| 2 |
CAM
Chesapeake Asset Management
New York
|
+$992K |
| 3 |
Morgan Stanley
New York
|
+$796K |
| 4 |
VF
Virtu Financial
New York
|
+$628K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$596K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAMS
Bellevue Asset Management (Switzerland)
Kuesnacht,
Switzerland
|
-$2.59M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$966K |
| 3 |
Jane Street
New York
|
-$786K |
| 4 |
Goldman Sachs
New York
|
-$214K |
| 5 |
FMA
FNY Managed Accounts
New York
|
-$138K |
BIS Hedge Fund Activity: Q2 2015 in Review
19 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2015, worth a combined $19.6M — down 1.4% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BIS positions and 5 closed out — a net gain of 6 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Highland Capital Management (Texas), adding an estimated $2.07M. The largest seller was Bellevue Asset Management (Switzerland), exiting entirely with an estimated $2.59M sold.
- 19 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2015, up from 13 in Q1 2015.
- Funds reported $19.6M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2015, down 1.4% quarter-over-quarter.
- 11 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2015 and 5 closed out, a net change of +6 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2015 was Highland Capital Management (Texas), an estimated $2.07M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2015 was Bellevue Asset Management (Switzerland), an estimated $2.59M sold.
Based on aggregated 13F filings for Q2 2015.